NVO Stock On Track For Worst Week In Over 6 Months After Strategy Day — Direct US Listing Talks, Drug Approval Fail To Halt Slip

Shares of Novo Nordisk (NVO) fell again on Wednesday as investors kept looking for nearer-term answers on pricing and competition to its obesity and diabetes drugs, even after CEO Mike Doustdar said the company is open to a direct NYSE listing and Singapore approved a new liver use for Wegovy.U.S…